Product Details

Zidovudine + Lamivudine Tablets BP 450 mg deliver a high-quality combination therapy that meets British Pharmacopoeia (BP) standards. This fixed-dose combination manages HIV-1 infection as part of a broader antiretroviral treatment regimen, combining dual nucleoside reverse transcriptase inhibitor action in a single tablet.

The tablets combine:

• Zidovudine, a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV viral replication by inhibiting reverse transcriptase enzyme activity, and
• Lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI) that suppresses HIV viral replication through the same reverse transcriptase inhibition pathway, working synergistically with Zidovudine.

Doctors commonly prescribe this combination as part of a combination antiretroviral therapy (cART) regimen for HIV-1 infection management. Hospitals, specialty clinics, and pharmacies rely on this formulation for its consistent quality and dependable therapeutic results. Our manufacturing process follows strict quality standards to guarantee high purity, accurate dosing, and reliable therapeutic efficacy in every batch.

Key Features

• BP-standard compliant combination therapy
• Supports HIV-1 management as part of antiretroviral therapy
• Delivers dual NRTI antiretroviral action
• Accurate 450 mg dosage per tablet
• Maintains a high-purity, stable formulation
• Uses hygienic blister packaging for safe storage
• Suits hospital, specialty clinic, and pharmacy use